GLP1R and type 2 diabetes mellitus: Specifically, the observation that one year of liraglutide treatment reduces plasma hsCRP by 35% (from a baseline level of 3.9 mg/L) in a randomized clinical trial in 3,731 obese patients without T2D, evidently shows that GLP-1 RA treatment has anti-inflammatory effects17.